These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 31558859)

  • 21. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.
    Miyoshi M; Mizuno M; Ishiki K; Nagahara Y; Maga T; Torigoe T; Nasu J; Okada H; Yokota K; Oguma K; Tsuji T
    J Gastroenterol Hepatol; 2001 Jul; 16(7):723-8. PubMed ID: 11446878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel and Effective Therapeutic Regimens for
    Hu Y; Zhu Y; Lu NH
    Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
    [No Abstract]   [Full Text] [Related]  

  • 23. Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication.
    Auesomwang C; Maneerattanaporn M; Chey WD; Kiratisin P; Leelakusolwong S; Tanwandee T
    J Gastroenterol Hepatol; 2018 Nov; 33(11):1822-1828. PubMed ID: 29804294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
    Murakami K; Sakurai Y; Shiino M; Funao N; Nishimura A; Asaka M
    Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
    Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
    Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication.
    Ozdil B; Akkiz H; Bayram S; Bekar A; Akgöllü E; Sandikçi M
    Turk J Gastroenterol; 2010 Mar; 21(1):23-8. PubMed ID: 20533108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
    Padol S; Yuan Y; Thabane M; Padol IT; Hunt RH
    Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Vallve M; Vergara M; Gisbert JP; Calvet X
    Aliment Pharmacol Ther; 2002 Jun; 16(6):1149-56. PubMed ID: 12030958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures.
    Goh KL; Manikam J; Qua CS
    Aliment Pharmacol Ther; 2012 May; 35(9):1097-102. PubMed ID: 22404486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different dose of new generation proton pump inhibitors for the treatment of
    Gao W; Zhang X; Yin Y; Yu S; Wang L
    Int J Immunopathol Pharmacol; 2021; 35():20587384211030397. PubMed ID: 34250840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison of Helicobacter pylori eradication rate according to different PPI-based triple therapy--omeprazole, rabeprazole, esomeprazole and lansoprazole--].
    Keum B; Lee SW; Kim SY; Kim JM; Choung RS; Yim HJ; Jeen YT; Lee HS; Chun HJ; Um SH; Choi JH; Kim CD; Ryu HS; Hyun JH
    Korean J Gastroenterol; 2005 Dec; 46(6):433-9. PubMed ID: 16371717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
    Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K
    J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Smoking and Drinking Did Not Increase the Failure of Therapeutic Helicobacter pylori Eradication by Vonoprazan, Clarithromycin, and Amoxicillin.
    Takara Y; Endo H; Nakano R; Kawachi K; Hidaka H; Matsunaga T; Tsuruoka N; Sakata Y; Shimoda R; Hara M; Fujimoto K
    Digestion; 2019; 99(2):172-178. PubMed ID: 30179876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potent gastric acid inhibition in Helicobacter pylori eradication.
    Gisbert JP
    Drugs; 2005; 65 Suppl 1():83-96. PubMed ID: 16335862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
    Sue S; Shibata W; Sasaki T; Kaneko H; Irie K; Kondo M; Maeda S
    J Gastroenterol Hepatol; 2019 Apr; 34(4):686-692. PubMed ID: 30151994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can Helicobacter pylori be eradicated with high-dose proton pump inhibitor in extensive metabolizers with the CYP2C19 genotypic polymorphism?
    Ormeci A; Emrence Z; Baran B; Soyer OM; Gokturk S; Evirgen S; Akyuz F; Karaca C; Besisik F; Kaymakoglu S; Ustek D; Demir K
    Eur Rev Med Pharmacol Sci; 2016 May; 20(9):1795-7. PubMed ID: 27212172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
    Suzuki S; Gotoda T; Kusano C; Iwatsuka K; Moriyama M
    Am J Gastroenterol; 2016 Jul; 111(7):949-56. PubMed ID: 27185079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age-dependent eradication of Helicobacter pylori with dual therapy.
    Treiber G; Ammon S; Klotz U
    Aliment Pharmacol Ther; 1997 Aug; 11(4):711-8. PubMed ID: 9305480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication.
    Kusunoki M; Yuki M; Ishitobi H; Kobayashi Y; Nagaoka M; Takahashi Y; Fukuba N; Komazawa Y; Shizuku T; Kinoshita Y
    Intern Med; 2019 Jun; 58(11):1549-1555. PubMed ID: 30713328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.